Marc Webster
Research Subjects
Marc Webster has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Andrew N. J. Tutt
The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK
1 shared publication - Anne Armstrong
The Christie NHS Foundation Trust, Manchester, United Kingdom
1 shared publication - Bienvenu Loembé
AstraZeneca (United Kingdom) 12 Cambridge
1 shared publication - Ed Casson
AstraZeneca 13 , Cambridge, United Kingdom
1 shared publication - Emma Dean
AstraZeneca (United Kingdom) 12 Cambridge
1 shared publication - Hendrik-Tobias Arkenau
Sarah Cannon Research Institute 6 , London, United Kingdom
1 shared publication
Latest Publications
- Open Access
- 20 October 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF12
Safety and Efficacy of Ceralasertib plus Olaparib for Advanced/Metastatic Triple-Negative Breast Cancer in Three Molecular Strata: The Phase II VIOLETTE Study
Purpose: VIOLETTE (NCT03330847) assessed olaparib alone or with ceralasertib (ATR inhibitor) or adavosertib (WEE1 inhibitor) as second-/third-line treatment in three molecular strata of patients with previously treated, poly (ADP-ribose) polymerase (PARP) inhibitor–naïve, advanced triple-negative breast cancer (TNBC). Patients and Methods: Patients were randomized 1:1:1 to olaparib 300 mg twice daily, ceralasertib 160 mg once daily (days 1–7; 28-day cycles) + olaparib 300 mg twice daily, or adavosertib 150 mg twice daily (days 1–3, 8–10; 21-day cycles) + olaparib 200 mg twice daily. Patients were stratified by the presence of tumoral homologous recombination repair (HRR) pathway mutations (m): BRCA1/2m, non-BRCA1/2m HRRm, or non-HRRm. The primary endpoint was progression-free survival (PFS) by blinded independent central review. Results: Two-hundred seventy three patients were randomized: 114, 112, and 47 to the olaparib, ceralasertib + olaparib, and adavosertib + olaparib arms, respectively. The adavosertib + olaparib arm was terminated early because of unacceptable toxicity. The median PFS of ceralasertib + olaparib was 7.4, 3.9, and 3.6 months in the BRCA1/2m, non-BRCA1/2m HRRm, and non-HRRm strata, respectively, and did not differ significantly from olaparib [hazard ratio (HR), 1.02 (90% confidence interval (CI), 0.63–1.66), 0.54 (90% CI, 0.28–1.03), and 0.76 (90% CI, 0.50–1.14), respectively]. In the non-HRRm group, objective response rates (ORR) were significantly improved for ceralasertib + olaparib (15.4%) versus olaparib [3.9%; odds ratio (OR), 4.45; 90% CI, 1.30–21.20; P = 0.0425]. No unexpected safety signals were reported for ceralasertib or olaparib. Conclusions: In patients with advanced PARP inhibitor (PARPi)–naïve non-HRRm TNBC, ceralasertib + olaparib significantly improved ORR versus olaparib. However, clinical significance is limited without improvement in PFS.
- 20 October 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF12
Open AccessSafety and Efficacy of Ceralasertib plus Olaparib for Advanced/Metastatic Triple-Negative Breast Cancer in Three Molecular Strata: The Phase II VIOLETTE Study
Purpose: VIOLETTE (NCT03330847) assessed olaparib alone or with ceralasertib (ATR inhibitor) or adavosertib (WEE1 inhibitor) as second-/third-line treatment in three molecular strata of patients with previously treated, poly (ADP-ribose) polymerase (PARP) inhibitor–naïve, advanced triple-negative breast cancer (TNBC). Patients and Methods: Patients were randomized 1:1:1 to olaparib 300 mg twice daily, ceralasertib 160 mg once daily (days 1–7; 28-day cycles) + olaparib 300 mg twice daily, or adavosertib 150 mg twice daily (days 1–3, 8–10; 21-day cycles) + olaparib 200 mg twice daily. Patients were stratified by the presence of tumoral homologous recombination repair (HRR) pathway mutations (m): BRCA1/2m, non-BRCA1/2m HRRm, or non-HRRm. The primary endpoint was progression-free survival (PFS) by blinded independent central review. Results: Two-hundred seventy three patients were randomized: 114, 112, and 47 to the olaparib, ceralasertib + olaparib, and adavosertib + olaparib arms, respectively. The adavosertib + olaparib arm was terminated early because of unacceptable toxicity. The median PFS of ceralasertib + olaparib was 7.4, 3.9, and 3.6 months in the BRCA1/2m, non-BRCA1/2m HRRm, and non-HRRm strata, respectively, and did not differ significantly from olaparib [hazard ratio (HR), 1.02 (90% confidence interval (CI), 0.63–1.66), 0.54 (90% CI, 0.28–1.03), and 0.76 (90% CI, 0.50–1.14), respectively]. In the non-HRRm group, objective response rates (ORR) were significantly improved for ceralasertib + olaparib (15.4%) versus olaparib [3.9%; odds ratio (OR), 4.45; 90% CI, 1.30–21.20; P = 0.0425]. No unexpected safety signals were reported for ceralasertib or olaparib. Conclusions: In patients with advanced PARP inhibitor (PARPi)–naïve non-HRRm TNBC, ceralasertib + olaparib significantly improved ORR versus olaparib. However, clinical significance is limited without improvement in PFS.